Related Experiment Video
Updated: Nov 24, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Atopic dermatitis: Tofacitinib, an option for refractory disease
Sineida Berbert Ferreira1, Rachel Berbert Ferreira2, Morton Aaron Scheinberg3
1Private Clinic - Dermatologia Dra. Sineida Berbert Ferreira Maringa Brazil.
Atopic dermatitis (AD) is a common skin condition impacting quality of life. This study shows oral tofacitinib effectively treated a patient with severe AD refractory to traditional therapies, achieving a complete response.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent inflammatory skin condition.
- Moderate-to-severe AD significantly impairs patients' quality of life.
- Current treatments for refractory AD are limited.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Tumor Immunotherapy

